Less than 2% of study participants reported a
serious medical event. None of them were
believed to be caused by the study vaccines.
Figure 3a: Side effects at the site of injection in at least 2% of people
Figure 3b: Other side effects in at least 2% of people
How has this study helped patients and researchers?
The results from this study indicate that giving The results from this study will be submitted to
shingles vaccine together with a pneumococcal regulatory agencies for evaluation and, if
vaccine does not impact the immune response to approved, will enable health care professionals
the vaccines in adults. The results from this study to give shingles vaccine together with a
did not raise any concern regarding the safety of pneumococcal vaccine to adults.
shingles vaccine and the pneumococcal vaccine.
.
Are there plans for further studies?
At the time of preparation of this summary, other The results of any future studies will be available
studies were ongoing to further evaluate shingles on the websites of European Medicines Agency
vaccine. and/or the United States National Institutes of
Health. Links are provided at the end of the
document.
*The use of the term side effects in this summary may be different to that in the Informed Consent or other
documents related to the vaccine.